Hafnia Ltd/ BMG4233B1090 /
27/03/2024 11:33:50 | Var. - | Volume | Denaro09:06:53 | Lettera09:00:00 | Capitalizzazione di mercato | Dividend Y. | Rapporto P/E |
---|---|---|---|---|---|---|---|
74.85NOK | - | 2,122 Fatturato: 158,831.70 |
-Quantità in denaro: - | -Quantità in lettera: - | 46.71 bill.NOK | - | - |
GlobeNewswire
21:00
First Federal Savings Bank and ICBA Offer Tips to Help Simplify the Homebuying Process
GlobeNewswire
19:39
QuidelOrtho (QDEL) Investors Who Suffered Substantial Losses After QDEL Reported Disastrous Q4 2023 ...
GlobeNewswire
19:02
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pret...
GlobeNewswire
16:00
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstr...
GlobeNewswire
16:00
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Gli...
GlobeNewswire
16:00
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...
GlobeNewswire
15:14
Flash News: OKX Announces Position Tier Adjustments for TURBO/USDT Perpetual Futures Listing
GlobeNewswire
15:00
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Ther...
GlobeNewswire
15:00
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monothera...
GlobeNewswire
14:15
FSLY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Fastly, Inc. Investors with ...
GlobeNewswire
14:15
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
GlobeNewswire
14:05
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting